
  Mrv15a5 07082217552D          

 19 20  0  0  0  0            999 V2000
    1.4289    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1434   -0.4125    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.1434   -1.2375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8579   -1.6500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8579   -2.4750    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1434   -2.8875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1434   -3.7125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4289   -4.1250    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.4289   -4.9500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7145   -5.3625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000   -4.9500    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000   -4.1250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7145   -3.7125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4289   -2.4750    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7145   -2.8875    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000   -2.4750    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4289   -1.6500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7145   -1.2375    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.7145   -0.4125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  4  5  2  0  0  0  0
  5  6  1  0  0  0  0
  6  7  1  0  0  0  0
  7  8  1  0  0  0  0
  8  9  1  0  0  0  0
  9 10  1  0  0  0  0
 10 11  1  0  0  0  0
 11 12  1  0  0  0  0
 12 13  1  0  0  0  0
  8 13  1  0  0  0  0
  6 14  2  0  0  0  0
 14 15  1  0  0  0  0
 15 16  1  0  0  0  0
 14 17  1  0  0  0  0
  3 17  2  0  0  0  0
 17 18  1  0  0  0  0
 18 19  1  0  0  0  0
M  END
>  <Catalog ID>
Z99601262

>  <MW>
266.16

>  <MW (desalted)>
266.34

>  <ClogP>
1.18

>  <Name>
Trimetazidine

>  <DrugBank ID>
DB09069

>  <MOA>
Trimetazidine is a selective long chain 3-ketoyl CoA thiolase inhibitor. Trimetazidine is an effective antianginal agent and a cytoprotective drug, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. It is a piperazine derivative indicated as an adjunct therapy in symptomatic treatment of stable angina pectoris.

>  <Target short>
ACAA2

>  <Targets>
3-ketoacyl-CoA thiolase, mitochondrial

>  <Disease Area>
agents affecting metabolism | anti-ischemic agent | anti-metabolic disorder agent | anti-myocardial infarction agent | anticachectic agent | anticonvulsive agent | antifibrotic agent | apoptosis inducing factor | cardioprotective agent | cytoprotective agent | cytotoxic agent | mitochondrial protective agent | myoprotective agent | toxic substance

>  <Smiles>
COC1=C(OC)C(OC)=C(CN2CCNCC2)C=C1

>  <CAS>
5011-34-7

>  <Description>
Trimetazidine is a selective long chain 3-ketoyl CoA thiolase inhibitor. Trimetazidine is an effective antianginal agent and a cytoprotective drug, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. It is a piperazine derivative indicated as an adjunct therapy in symptomatic treatment of stable angina pectoris.

>  <Activity coefficients and values>
IC50 - 75 nM

>  <References>
Curr. Pharm. Des., 2002, vol. 8, # 14, p. 1199 - 1227

>  <Phase>
approved; investigational

>  <Indication>
angina pectoris

$$$$

  Mrv15a5 07082217552D          

 11 11  0  0  0  0            999 V2000
    2.0572    1.7262    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2448    1.8695    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7145    1.2375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1842    1.8695    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4289    0.8250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4289    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1434   -0.4125    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.7145   -0.4125    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7145   -0.4125    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.8250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  3  5  1  0  0  0  0
  5  6  1  0  0  0  0
  6  7  2  0  0  0  0
  6  8  1  0  0  0  0
  8  9  1  0  0  0  0
  9 10  2  0  0  0  0
  9 11  1  0  0  0  0
  3 11  1  0  0  0  0
M  END
>  <Catalog ID>
Z99599698

>  <MW>
155.09

>  <MW (desalted)>
155.19

>  <ClogP>
0.95

>  <Name>
Bemegride

>  <MOA>
Bemegride is a central nervous system stimulant and antidote for barbiturate poisoning. Bemegride has an antagonistic action on the GABA A receptor, suppressing both GABA- and pentobarbitone-evoked whole-cell currents to similar extents.

>  <Target short>
GABA A receptor

>  <Disease Area>
CNS stimulants; Antidots

>  <Smiles>
CCC1(C)CC(=O)NC(=O)C1

>  <CAS>
64-65-3

>  <Description>
Bemegride is a CNS stimulant that is used to induce convulsions in experimental animals. It has also been used as a respiratory stimulant and in the treatment of barbiturate overdose.

>  <Activity coefficients and values>
pKi - 5 - | pKi - 5 - | pKi - 5 -

>  <References>
EUR. J. PHARMACOL., 1995, vol. 286, # 2, p. 137 - 146 | EUR. J. PHARMACOL., 1995, vol. 286, # 2, p. 137 - 146 | EUR. J. PHARMACOL., 1995, vol. 286, # 2, p. 137 - 146

>  <Phase>
Experimental

>  <Indication>
poison antidote

$$$$

  Mrv15a5 07082217552D          

 19 20  0  0  0  0            999 V2000
    0.0000   -4.9500    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.7145   -5.3625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7145   -6.1875    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.4289   -4.9500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1434   -5.3625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8579   -4.9500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8579   -4.1250    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.5724   -5.3625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2868   -4.9500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0013   -5.3625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0013   -6.1875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2868   -6.6000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5724   -6.1875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7158   -6.6000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4302   -6.1875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1447   -6.6000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1447   -7.4250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4302   -7.8375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7158   -7.4250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  2  0  0  0  0
  2  4  1  0  0  0  0
  4  5  1  0  0  0  0
  5  6  1  0  0  0  0
  6  7  2  0  0  0  0
  6  8  1  0  0  0  0
  8  9  1  0  0  0  0
  9 10  2  0  0  0  0
 10 11  1  0  0  0  0
 11 12  2  0  0  0  0
 12 13  1  0  0  0  0
  8 13  2  0  0  0  0
 11 14  1  0  0  0  0
 14 15  1  0  0  0  0
 15 16  2  0  0  0  0
 16 17  1  0  0  0  0
 17 18  2  0  0  0  0
 18 19  1  0  0  0  0
 14 19  2  0  0  0  0
M  END
>  <Catalog ID>
Z99599540

>  <MW>
254.09

>  <MW (desalted)>
254.28

>  <ClogP>
3.14

>  <Name>
Fenbufen

>  <DrugBank ID>
DB08981

>  <MOA>
Fenbufen is a non-steroidal anti-inflammatory drug and a prodrug form of 4-biphenylacetic acid. Fenbufen was previously used in the treatment of osteoarthritis and inflammatory pain.

>  <Target short>
PTGS1, PTGS2

>  <Targets>
Acetylcholinesterase (peptide) | 72 kda type iv collagenase | 72kDa type IV collagenase | Aldo-keto reductase family 1 member C3 | Prostaglandin G/H synthase 1 | Prostaglandin G/H synthase 2

>  <Disease Area>
antibiotic agent | antiinflammatory agent | antioxidant | antitoxoplasmic agent | cytotoxic agent | inhibitory activity | nonsteroid antiinflammatory agent

>  <Smiles>
OC(=O)CCC(=O)C1=CC=C(C=C1)C1=CC=CC=C1

>  <CAS>
36330-85-5

>  <Description>
Fenbufen is a non-steroidal anti-inflammatory drug and a prodrug form of 4-biphenylacetic acid. Fenbufen was previously used in the treatment of osteoarthritis and inflammatory pain.

>  <Activity coefficients and values>
IC50 - 0.97 µM | IC50 - 1000 nM | IC50 - 1000 nM | IC50 - 0.001 mM | IC50 - 3.9 µM | IC50 - 8.1 µM

>  <References>
Chem. Biodivers., 2021, vol. 18, # 2 | Bayer Corporation - US5789434, 1998, A | Harold Clinton Eugene Kluender; Kerry Jeanne Combs; Brian Richard Dixon; Stephan Schneider; Jill Elizabeth Wood; Michael Christopher VanZandt; Donald John Wolanin; Scott M. Wilhelm; Guenter Hans Heinz Herbert Benz; David Ross Brittelli; William Harrison Bullock - US6166082, 2000, A | ARCH. BIOCHEM. BIOPHYS., 1992, vol. 296, # 1, p. 17 - 26 | Eur. J. Med. Chem., 2009, vol. 44, # 9, p. 3798 - 3804 | Eur. J. Med. Chem., 2009, vol. 44, # 9, p. 3798 - 3804

>  <Phase>
approved

>  <Indication>
pain relief

$$$$

  Mrv15a5 07082217552D          

 16 17  0  0  0  0            999 V2000
    5.4957    2.3479    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7812    1.9354    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0668    2.3479    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.3523    1.9354    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3523    1.1104    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6378    0.6979    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9233    1.1104    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1387    0.8555    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.6538    1.5229    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1387    2.1904    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    1.9233    1.9354    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6378    2.3479    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1712    1.5229    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9962    1.5229    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1712    2.3479    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1712    0.6979    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  4  5  1  0  0  0  0
  5  6  2  0  0  0  0
  6  7  1  0  0  0  0
  7  8  1  0  0  0  0
  8  9  2  0  0  0  0
  9 10  1  0  0  0  0
 10 11  1  0  0  0  0
  7 11  2  0  0  0  0
 11 12  1  0  0  0  0
  4 12  2  0  0  0  0
  9 13  1  0  0  0  0
 13 14  2  0  0  0  0
 13 15  2  0  0  0  0
 13 16  1  0  0  0  0
M  END
>  <Catalog ID>
Z995241886

>  <MW>
258.01

>  <MW (desalted)>
258.32

>  <ClogP>
2.05

>  <Name>
ethoxzolamide

>  <MOA>
carbonic anhydrase inhibitor

>  <Target short>
CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9

>  <Disease Area>
ophthalmology, gastroenterology

>  <Smiles>
CCOc1ccc2nc(sc2c1)S(N)(=O)=O

>  <CAS>
452-35-7

>  <Description>
Ethoxzolamide is a sulfonamide. It inhibits carbonic anhydrase activity. It was used in the treatment of glaucoma and duodenal ulcers, and as a diuretic, but is now withdrawn.

>  <Activity coefficients and values>
Kd (dissociation constant) - 0.15 nM | Ki (inhibition constant) - 0.25 nM | IC50 - 0.25 nM | Ki (inhibition constant) - 0.5 nM | Ki (inhibition constant) - 0.69 nM | Ki (inhibition constant) - 0.69 nM | Ki (inhibition constant) - 0.7 nM | Ki (inhibition constant) - 0.8 nM | IC50 - 0.001 µM

>  <References>
Angew. Chem. Int. Ed. Engl., 2005, vol. 44, p. 116 - 120 | Eur. J. Med. Chem., 1998, vol. 3, # 7 - 8, p. 577 - 594 | Eur. J. Med. Chem., 2013, vol. 62, p. 597 - 604 | Curr. Med. Chem. Imun. Endoc. and Metab. Agents., 2001, vol. 1, # 1, p. 61 - 97 | Bioorg. Med. Chem., 2016, vol. 24, # 5, p. 1115 - 1120 | J. Med. Chem., 2013, vol. 56, # 4, p. 1761 - 1771 | Eur. J. Med. Chem., 1997, vol. 32, p. 311 - 319 | Curr. Pharm. Des., 2008, vol. 14, # 7, p. 641 - 648 | Rev. Roumaine Chim., 1992, vol. 37, # 7, p. 849 - 856

>  <Phase>
Withdrawn

>  <Indication>
glaucoma, duodenal ulcer disease

$$$$

  Mrv15a5 07082217552D          

 13 13  0  0  0  0            999 V2000
    0.0000   -2.4750    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.7145   -2.8875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4289   -2.4750    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4289   -1.6500    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.1434   -2.8875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8579   -2.4750    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.5724   -2.8875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2868   -2.4750    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0013   -2.8875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0013   -3.7125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7158   -4.1250    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    4.2868   -4.1250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5724   -3.7125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  3  5  1  0  0  0  0
  5  6  1  0  0  0  0
  6  7  1  0  0  0  0
  7  8  1  0  0  0  0
  8  9  2  0  0  0  0
  9 10  1  0  0  0  0
 10 11  1  0  0  0  0
 10 12  2  0  0  0  0
 12 13  1  0  0  0  0
  7 13  2  0  0  0  0
M  END
>  <Catalog ID>
Z995094004

>  <MW>
202.04

>  <MW (desalted)>
202.63

>  <ClogP>
1.22

>  <Name>
Chlorphenesin

>  <DrugBank ID>
DB00856

>  <MOA>
Chlorphenesin is a phenol ether used to treat painful muscular conditions.

>  <Disease Area>
antifungal agent | muscle relaxant agent

>  <Smiles>
OCC(O)COC1=CC=C(Cl)C=C1

>  <CAS>
104-29-0

>  <Description>
Chlorphenesin is a phenol ether used to treat painful muscular conditions.

>  <Phase>
approved; experimental

>  <Indication>
muscle relaxant, sedative

$$$$

  Mrv15a5 07082217552D          

  9  8  0  0  1  0            999 V2000
    1.9520    1.9520    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.9520    1.1270    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    1.2375    0.7145    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5230    1.1270    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1914    0.7145    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.5230    1.9520    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.6664    0.7145    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3809    1.1270    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.6664   -0.1105    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  6  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  4  5  2  0  0  0  0
  4  6  1  0  0  0  0
  2  7  1  0  0  0  0
  7  8  2  0  0  0  0
  7  9  1  0  0  0  0
M  END
>  <Catalog ID>
Z995084132

>  <MW>
133.04

>  <MW (desalted)>
133.1

>  <ClogP>
-2.41

>  <Name>
Aspartic acid

>  <DrugBank ID>
DB00128

>  <MOA>
L-Aspartic acid is an amino acid commonly found as a component in total parenteral nutrition. It serves as a precursor for synthesis of proteins, oligopeptides, purines, pyrimidines, nucleic acids and L-arginine. It can also promote energy production via its metabolism in the Krebs cycle.

>  <Target short>
Ionotropic glutamate NMDA receptor pX=7.0 | Excitatory amino acid transporter 4 pX=6.01 | Metabotropic glutamate receptor 6 pX=6.0 | Metabotropic glutamate 8a receptor pX=6.0 | Metabotropic glutamate 7a receptor pX=6.0

>  <Targets>
Ionotropic glutamate NMDA receptor | Excitatory amino acid transporter 4 | Metabotropic glutamate 8a receptor | Metabotropic glutamate 7a receptor | Metabotropic glutamate receptor 6 | Glutamate receptor ionotropic, NMDA 2D | Excitatory amino acid transporter | kainate selective glutamate receptor | Excitatory amino acid transporter 1 | Metabotropic glutamate receptor 5

>  <Disease Area>
Proliferative | antibacterial agent | antibiofilm agent | antibiotic agent | antifungal agent | antiglycation agent | antiplasmodial agent | antitrichomonal agent | dipeptidyl carboxypeptidase inhibitor | enzyme activator | inhibitory activity | protective agent

>  <Smiles>
N[C@@H](CC(O)=O)C(O)=O

>  <CAS>
56-84-8

>  <Description>
L-Aspartic acid is an amino acid commonly found as a component in total parenteral nutrition. It serves as a precursor for synthesis of proteins, oligopeptides, purines, pyrimidines, nucleic acids and L-arginine. It can also promote energy production via its metabolism in the Krebs cycle.

>  <Activity coefficients and values>
IC50 - 0.1 µM | Km (Michaelis constant) - 0.97 µM | Ki (inhibition constant) - 1 µM | Ki (inhibition constant) - 1 µM | Ki (inhibition constant) - 1 µM

>  <References>
Br. J. Pharmacol., 1988, vol. 95, # 3, p. 932 - 938 | Oregon Health Science University - US5912171, 1999, A | Naunyn-Schmiedeberg's Arch. Pharmacol., 2000, vol. 362, # 6, p. 546 - 554 | Naunyn-Schmiedeberg's Arch. Pharmacol., 2000, vol. 362, # 6, p. 546 - 554 | Naunyn-Schmiedeberg's Arch. Pharmacol., 2000, vol. 362, # 6, p. 546 - 554

>  <Phase>
approved; nutraceutical

$$$$

  Mrv15a5 07082217552D          

 10  8  0  0  1  0            999 V2000
    0.0000    0.0000    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    2.3571    0.1833    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.0716   -0.2292    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7861    0.1833    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5006   -0.2292    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2150    0.1833    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    5.2150    1.0083    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.9295   -0.2292    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.6440    0.1833    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.9295   -1.0542    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  4  5  1  0  0  0  0
  5  6  1  0  0  0  0
  6  7  1  6  0  0  0
  6  8  1  0  0  0  0
  8  9  2  0  0  0  0
  8 10  1  0  0  0  0
M  END
>  <Catalog ID>
Z991547388

>  <MW>
168.07

>  <MW (desalted)>
132.16

>  <ClogP>
-3.95

>  <Name>
Ornittine hydrochloride

>  <DrugBank ID>
DB00129

>  <MOA>
L-ornithine hydrochloride has an antifatigue effect by increasing the efficiency of energy consumption and promoting the excretion of ammonia. It is one of the key reactants in the urea cycle.

>  <Disease Area>
infectious disease

>  <Smiles>
Cl.NCCC[C@H](N)C(O)=O

>  <CAS>
3184-13-2

>  <Description>
L-ornithine hydrochloride has an antifatigue effect by increasing the efficiency of energy consumption and promoting the excretion of ammonia. It is one of the key reactants in the urea cycle.

>  <Phase>
approved; nutraceutical

$$$$